NEW YORK (GenomeWeb News) – Myriad Genetics said during its analyst and investor day today that it will launch a new multi-hereditary cancer panel, called myRisk Hereditary Cancer, by the end of this year that will replace its existing BRACAnalysis and other hereditary cancer tests by the summer of 2015.

The new panel will initially focus on breast, colon, ovarian, endometrial, and pancreatic cancer, as well as melanoma, and will expand to lung, prostate, and other cancers in the future, Mark Capone, president of Myriad Genetics Laboratories, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.